Company news

Bio-thera Solutions, Ltd. Class A (SSE:688177) news

Bio-thera Solutions, Ltd. Class A news releases on 6ix. Latest, Sep 8, 2026: "Bio-Thera Solutions, Ltd."Announcement on Attending the 2026 Collective…

Bio-thera Solutions, Ltd. Class A (SSE:688177) news

Press releases & updates

"Bio-Thera Solutions, Ltd."Announcement on Attending the 2026 Collective Reception Day for Investors in Guangdong Jurisdiction and Interim Performance Briefing for Listed Companies in the Jurisdiction

"Bio-Thera Solutions, Ltd."Announcement on Resignation of the Chief Financial Officer and Designation of the Chairman and the General Manager to Act as the Chief Financial Officer

"Bio-Thera Solutions, Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026

"Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for Supplementary Application for Bevacizumab Injection (POBEVCY)

"Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure Regarding the Progress of Receipt of Milestone Payment under the License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) Injection

"Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid Tumors

"Bio-Thera Solutions, Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

Announcement on the Status of the EU GMP Inspection at the Yonghe Facility

Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of BAT2206 (Ustekinumab Injection) by Singapore HSA

Announcement on Obtaining Drug Registration Certificate for ICHALIG®/XICHALIG® (Ustekinumab Injection)

Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi(R) and Simponi Aria(R)

Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT8013 for Injection

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

Announcement on Loan Application Business of the Wholly-owned Subsidiary and the Company's Provision of Guarantee

Notice on Convening the 2nd Extraordinary General Meeting in 2026

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT3306 Combined with BAT8008 for Treatment for Advanced Solid Tumors

Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Progress in Commercialization Agreement with STADA for BAT2506 (Golimumab) Injection

Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in India

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT8008 Combined with BAT1006 and Trastuzumab of Advanced Solid Tumors

Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Usymro (Ustekinumab Injection) by UK MHRA

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Acceptance of the Marketing Authorization Application for Batopoizumab Injection (BAT4406F)

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

Announcement on Marketing Authorization Approval of Gotenfia (Golimumab Injection) by European Medicines Agency (EMA)

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Voluntary Disclosure of Execution of a License, Manufacturing, Supply, and Commercialization Agreement with Avalon Pharma Regarding BAT3306 (Pembrolizumab) Injection

Announcement on Changing Sponsor Representative

Announcement on Expected Loss in Performance for 2025

Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital

Announcement on Signing a Project Construction Work Contract by the Wholly-owned Subsidiary and Related Party and Related Party Transactions

Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization, Production, Supply and Commercialization Agreement with Gedeon Richter Plc. (Richter Gedeon) for BAT2206 (Ustekinumab) Injection

Announcement on Voluntary Disclosure of Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (Ustekinumab) Injection

Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Sandoz AG for BAT1706 (Bevacizumab) Injection

Announcement on Estimated Daily Related Party Transactions in 2026

Announcement on Obtaining Government Subsidies

Announcement on Acceptance of Marketing Authorization Application for Vilacita Monoclonal Antibody Injection (BAT5906)

Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion

Announcement on Convening the Q3 2025 Performance Briefing

Report for Q3 2025

Announcement on Voluntary Disclosure of Progress in the Receipt of the Initial Payment from STADA for the Signing of the Licensing and Commercialization Agreement for BAT1806 (Tocilizumab) Injection

Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in Canada

Announcement on the Resignation of Core Technical Personnel

Announcement on Completing Industrial and Commercial Change Registration of Registered Address and Amending the Articles of Association

Announcement on Attending 2025 Online Collective Reception Day for Investors in Guangdong Jurisdiction

Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) Injection

Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Qletli (Adalimumab Solution for Injection) by UK MHRA

Announcement on Convening the Semi-annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2025

Notice on Convening the 2nd Extraordinary General Meeting in 2025